55 分钟on MSN
NeurAxis outlines commercial readiness for 2026 as double-digit growth continues and CPT ...
Q3 2025 Management View Brian Carrico, President, CEO & Director, emphasized "the continued execution of our commercialization strategy for IB-Stim, our neuromodulation technology for both the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果